Терализумаб

Also known as TGN1412, CD28-SuperMAB, TAB08

Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (), a spin-off of the University of Würzburg around immunologist Thomas Hünig, co-founder and chief scientific officer (CSO) Thomas Hanke and chief executive officer (CEO) Benedikte Hatz went bankrupt later that year. The c